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Objectives The aim of this study was to evaluate long-term clinical outcomes after percutaneous
coronary intervention (PCI) for chronic total occlusions (CTO).
Background Despite technical advancements, there is a paucity of data on long-term outcomes
after PCI of CTO.
Methods We evaluated long-term clinical outcomes in 1,791 patients who underwent PCI of 1,852
CTO at 3 tertiary care centers in the United States, South Korea, and Italy between 1998 and 2007.
Median follow-up was 2.9 years (interquartile range: 1.5 to 4.6 years).
Results Procedural success was obtained in 1,226 (68%) patients. Stents were implanted in 1,160
patients (95%); 396 patients (34%) received bare-metal stents (BMS), and 764 patients (66%) re-
ceived drug-eluting stents (DES). After multivariable analysis, successful CTO PCI was an indepen-
dent predictor of a lower cardiac mortality (hazard ratio [HR]: 0.40, 95% conﬁdence interval [CI]: 0.21
to 0.75, p  0.01) and reduced need for coronary artery bypass graft surgery (HR: 0.21, 95% CI: 0.13
to 0.40, p  0.01); it also correlated with a strong trend toward lower all-cause mortality (HR: 0.63,
95% CI: 0.40 to 1.00, p  0.05) at 5-year follow-up. Among patients who underwent stent implanta-
tion, treatment with DES rather than BMS resulted in less target vessel revascularization at long-term
follow-up (17.2% vs. 31.1%, p  0.01); deﬁnite/probable stent thrombosis rates were similar (DES
1.7%, BMS 2.3%, p  0.58). Within the DES subgroup, patients treated with paclitaxel-eluting stents
and sirolimus-eluting stents had similar clinical outcomes.
Conclusions Successful CTO PCI is associated with reduced long-term cardiac mortality and need for coro-
nary artery bypass graft surgery. Treatment of CTO with DES rather than BMS is associated with a signiﬁcant
reduction in target vessel revascularization with similar rates of stent thrombosis. Paclitaxel-eluting stents and
sirolimus-eluting stents had similar long-term safety and efﬁcacy outcomes. (J Am Coll Cardiol Intv 2011;4:
952–61) © 2011 by the American College of Cardiology Foundation
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953The percutaneous treatment of chronic total occlusions
(CTO) is 1 of the major challenges in contemporary
interventional cardiology. These complex lesions are iden-
tified in 15% to 30% of all patients referred for coronary
angiography (1,2). Percutaneous coronary intervention
(PCI) of CTOs is technically challenging and requires famil-
iarity with advanced interventional techniques as well as specialty
See page 962
equipment. The complexity of percutaneous treatment of
CTOs is illustrated by the relatively low procedural success
rates (70% to 86%), compared with subtotal stenoses (98%)
(3–6). Moreover, even in case of a successful procedure,
PCI of a CTO is hampered by high restenosis rates.
Nonetheless, successful PCI of a CTO can be associated
with symptom relief, lower rate of subsequent myocardial
infarction (MI), coronary artery bypass graft (CABG) sur-
gery, and improved long-term survival, compared with
unsuccessful PCI (7–11). Most of these studies, however,
were not randomized, and many of them were performed
with balloon-angioplasty or bare-metal stents (BMS), pos-
sibly explaining the relatively high re-occlusion rates.
The introduction of drug-eluting stents (DES) has dra-
matically reduced restenosis rates after PCI, compared with
BMS, and might also have also impacted the percutaneous
treatment of CTOs (12). A recent meta-analysis showed
DES use in CTO recanalization is associated with lower
target vessel revascularization (TVR) (13). However, there
was also a statistical trend toward a higher risk of stent
thrombosis with DES, compared with BMS. Currently,
long-term data on clinical outcomes after CTO recanaliza-
tion are scarce. Therefore, the aim of the current study was
to identify the long-term clinical outcome of patients with
successful versus failed CTO recanalization and the long-
term safety and efficacy of DES versus BMS in CTOs.
Methods
All patients who underwent PCI for at least 1 CTO at 3
tertiary care hospitals between 1998 and 2007 were included
in this study. A CTO was defined as a coronary artery
obstruction with a Thrombolysis In Myocardial Infarction
(TIMI) flow grade 0. All patients included had a native
vessel occlusion estimated to be of at least 3-month duration
on the basis of a history of sudden chest pain, a previous MI
in the same target vessel territory, or the time between
diagnosis made on coronary angiography and PCI. All
patients had symptomatic angina and/or a positive func-
tional ischemia study.
The PCI and stent implantation were performed in a
standard manner. Heparin was administered to maintain an
activated clotting time 250 s. The use of BMS or DES as
well as the use of glycoprotein IIb/IIIa inhibitors was left tothe discretion of the treating physician. The PCI of the
CTO was performed with contemporary techniques such as
bilateral injection; specialized hydrophilic, tapered tip, and
stiff wires; parallel wires; microcatheters; and retrograde
approach when they became available. After PCI, all pa-
tients were prescribed lifelong aspirin; in addition clopi-
dogrel was prescribed for at least 3 months after DES
implantation in Italy and South Korea and for at least 12
months in the United States and at least 1 month after BMS
implantation in all participating sites.
Demographic and procedural data with regard to all
patients undergoing PCI at the 3 participating centers were
prospectively entered into a ded-
icated database. Angiographic
analyses were performed by on-
line QCA assessment by the op-
erators. Patients were followed
prospectively by telephone inter-
view or outpatient visit after 30
days and yearly thereafter. The
following endpoints were evalu-
ated to compare patients with a
failed versus a successful proce-
dure: all-cause death, cardiac
death, MI, and CABG. To
compare patients treated with a
DES versus BMS the following
endpoints were evaluated: the
composite clinical endpoint of
major adverse cardiac events
(MACE) (all-cause death, MI,
or TVR), all-cause death, car-
diac death, MI, TVR, and defi-
nite/probable stent thrombosis
according to the Academic Re-
search Consortium definitions
(14). The following definitions
were used: cardiac death was de-
fined as death within 7 days after
MI or stroke, death associated
with cardiovascular interven-
tions within 30 days after
CABG or within 7 days after PCI, or unexpected death
presumed to be due to ischemic cardiovascular disease and
occurring within 24 h after the onset of symptoms without
clinical or postmortem evidence of another cause. Death
from uncertain causes was also classified as cardiac death.
In-hospital MI was defined as a rise of creatine phospho-
kinase or creatine kinase-myocardial band isoenzyme 3
upper limit of normal. Multivessel disease was defined as the
presence of at least 1 stenosis 70% by visual assessment in
another major epicardial vessel or its sidebranches than that
where the CTO was located. Procedural success was defined
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass graft surgery
CI  confidence interval
CTO  chronic total
occlusion
DES  drug-eluting stent(s)
HR  hazard ratio
LAD  left anterior
descending coronary artery
LVEF  left ventricular
ejection fraction
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
TIMI  Thrombolysis In
Myocardial Infarction
TVR  target vessel
revascularizationas successful recanalization and dilation of at least 1 CTO/
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954patient with or without stent implantation, residual stenosis
of 50%, and TIMI flow grade 2.
Data are presented as the mean  SD or as percentages.
vent rates were estimated with the Kaplan-Meier method.
ollow-up was censored at date of last follow-up or at 5
ears, whichever came first. Survival curves with all available
ollow-up data were constructed for time-to-event variables
ith Kaplan-Meier methodology and compared by log-rank
est. Data on patients who were lost to follow-up were
ensored at the time of the last contact. Cox proportional
azards methods were used to identify the predictors of
ll-cause mortality, cardiac mortality, MI, and CABG at 5
ears among patients with successful versus unsuccessful
CI and TVR at 5 years in patients undergoing successful
CI with BMS versus DES. The multivariable model was
uilt by stepwise variable selection with entry and exit
riteria set at the p  0.1 level. The following patient level
andidate predictors were evaluated: age (per-year incre-
Figure 1. Study Flow Chart
*Procedural success was deﬁned as successful recanalization and dilation of at
residual stenosis of 50%, and Thrombolysis In Myocardial Infarction ﬂow gra
successful, and the recanalization of the other failed.ent), sex, hypercholesterolemia, hypertension, diabetes
ellitus, smoking, chronic kidney disease, pre-procedural
eft ventricular ejection fraction (LVEF) (per-10%), prior
I, multivessel disease, CTO located in the left anterior
escending coronary artery (LAD), total CTO length
mm), and total stent length (mm). A smaller number of
ovariates were evaluated for the low-frequency endpoint of
ardiac death (age, LVEF, diabetes mellitus, chronic kidney
isease, prior MI, and CTO located in LAD). This selec-
ion was made on the basis of the well-known association of
hese covariates with cardiac mortality. Statistical analyses
ere performed with SPSS (version 17.0, SPSS, Inc.,
hicago, Illinois).
esults
Between 1998 and 2007, a total of 1,852 CTO lesions were
attempted in 1,791 patients. Figure 1 shows the patient
1 chronic total occlusion (CTO)/patient with or without stent implantation,
. **Includes 23 patients with 2 attempted CTOs, of which 1 CTO lesion wasleast
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955treatment flow. Baseline characteristics of all patients are
summarized in Table 1. Procedural success (after re-
attempts) was obtained in 1,226 patients (68%). Annual
success rates ranged from 51.4% to 77.1%, and there was a
significant statistical trend indicating success rates increased
over time (p  0.01) (Fig. 2). Among the 61 patients with
attempted CTO lesions, the procedural outcome was
uccessful PCI of both lesions in 30 patients (49%), suc-
essful PCI of only 1 lesion in 23 patients (38%), and failed
Table 1. Baseline Demographic, Angiographic, and Procedural
Characteristics of Patients Who Underwent Successful and Unsuccessful
PCI of a CTO
Successful PCI
(n  1,226)
Failed PCI
(n  565) p Value
Baseline characteristics
Age (yrs) 61.2 10.7 62.1 10.4 0.10
Male 84.8% 89.0% 0.02
Hypertension 60.0% 59.2% 0.79
Smoking 23.0% 28.0% 0.03
Diabetes mellitus 23.1% 21.9% 0.58
Hypercholesterolemia 66.2% 60.7% 0.03
Prior MI 46.7% 56.4% 0.01
Prior CABG 13.6% 20.9% 0.01
Ejection fraction (%) 53.8 10.0 52.6 10.7 0.04
CKD 3.1% 4.0% 0.32
Angiographic and procedural
characteristics
Number of CTOs
attempted/patient
1.02 0.15 1.05 0.22 0.01
Number of CTOs
revascularized
1,256 0
CTO located in 0.12
LAD 37.0% 28.4%
Circumﬂex 24.0% 23.9%
RCA 40.9% 48.5%
Left main 0.4% 0.3%
Multivessel disease 64.9% 75.3% 0.01
CTO length (mm) 22.3 15.6 26.3 14.3 0.01
Number of stents* 1.6 1.0 NA NA
Stent length (mm)* 40.8 24.9 NA NA
Stent type*
BMS 34.1% NA NA
SES 47.8% NA NA
PES 17.8% NA NA
Other DES type 0.3% NA NA
Double coronary injection 27.8% 23.9% 0.09
Residual dissection 4.3% 9.4% 0.01
Coronary perforation
during procedure
1.7% 7.4% 0.01
Total amount of contrast
used
433 232 481 222 0.46
Values are mean SD or %. *Values apply to 1,160 patients who received stents.
BMS  bare-metal stent(s); CABG  coronary artery bypass surgery; CKD  chronic kidney
disease; CTO chronic total occlusion; DES drug-eluting stent(s); LAD left anterior descend-
ing coronary artery;MImyocardial infarction; PCIpercutaneous coronary intervention; PES0paclitaxel-eluting stent(s); RCA right coronary artery; SES sirolimus-eluting stent(s).PCI of both lesions in 8 patients (13%). Success rates after
reattempts were 73.0% (276 of 378 patients) in Columbia
University Medical Center, 81.3% in Asan Medical Center
(217 of 267 patients), and 64.0% in San Raffaele Hospital,
Milan (733 of 1,146 patients). Compared with patients who
had a successful procedure, patients who had a failed
procedure were more often male and smokers, more often
had a history of prior MI and prior CABG, less often had
hypercholesterolemia, and had a lower pre-procedural
LVEF. Furthermore, they more often had multivessel
coronary artery disease, longer occlusion lengths, and more
often had complicated procedures with coronary dissections
and perforations. After successful recanalization, stents
were implanted in 1,160 patients (95%). Drug-eluting
stents were used in 764 of the 1,160 patients who
received a stent (66%).
Median follow-up in this cohort was 2.9 years (interquar-
tile range: 1.5 to 4.6 years). Kaplan-Meier curves for clinical
endpoints at 5 years are shown in Figure 3. Patients with
successful CTO PCI had significantly lower rates of all-
cause mortality (6.0% vs. 8.6%, p  0.01), cardiac mortality
3.0% vs. 5.8%, p  0.01), and CABG (3.2% vs. 13.3%,
 0.01).
Table 2 shows independent predictors of all-cause mor-
ality, cardiac mortality, MI, and CABG at 5-year follow-
p. Successful PCI of a CTO continued to be associated
ith lower cardiac mortality (hazard ratio [HR]: 0.40, 95%
onfidence interval [CI]: 0.21 to 0.75, p  0.01) and a
educed need for CABG (HR: 0.21, 95% CI: 0.13 to 0.40,
 0.01). Moreover, we observed a trend toward lower
ll-cause mortality with successful PCI (HR: 0.63, 95% CI:
Figure 2. Annual Success Rates of CTO PCI in the Multinational
CTO Registry
Success rates after reattempts ranged from 51.4% to 77.1%; there was a
signiﬁcant statistical trend indicating success rates increased over time.
CTO  chronic total occlusion; PCI  percutaneous coronary intervention..40 to 1.00, p  0.05).
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956We compared, as a secondary analysis, long-term clinical
outcomes in patients with failed CTO PCI who subse-
quently underwent CABG (n  59, 11.3%) versus those
who did not (n 461, 88.7%). There were no differences in
ortality (CABG 6.9% vs. no CABG 8.8%, p  0.99) or
I (CABG 5.9% vs. no CABG 5.3%, p  0.78) at
ong-term follow-up among patients who underwent
ABG and those who did not.
DES versus BMS for PCI of a CTO. The temporal relation of
tent use was as follows: BMS exclusively 1998 to January
002 (n  258), and DES predominantly after they became
vailable (2002 to 2007, n  764 DES, n  204 BMS).
aseline characteristics of patients who underwent success-
ul PCI of a CTO and underwent DES or BMS implan-
ation are shown in Table 3. Of 764 patients treated with
ES, 555 (72.6%) received Cypher sirolimus-eluting stents
SES) (Cordis, Warren, New Jersey), 206 (27.0%) received
axus paclitaxel-eluting stents (PES) (Boston Scientific,
Figure 3. Clinical Event Rates in Patients Who Underwent Successful and
Unadjusted Kaplan-Meier rates plotted. CABG  coronary artery bypass graft satick, Massachusetts), 2 patients received Endeavor aotarolimus-eluting stents (Medtronic, Santa Rosa, Califor-
ia), and 1 patient received a Costar PES (Cordis). When
ompared with BMS-treated patients, DES-treated pa-
ients more often had diabetes mellitus, hypertension,
moking, hypercholesterolemia, and chronic kidney disease
nd less often had a prior MI.
The median follow-up duration for patients who under-
ent successful PCI of a CTO was 3.0 years (interquartile
ange: 2.0 to 4.5 years). Kaplan-Meier curves of 5-year
linical event rates are shown in Figure 4. The long-term
ACE rate was significantly lower among patients treated
ith DES (24.3% vs. 36.9%, p  0.01), entirely due to a
reduced need for TVR (31.1% vs. 17.0%, p  0.01). The
incidence of definite/probable stent thrombosis at 5-year
follow-up was similar in both groups (DES 1.8% vs. BMS
2.3%, p  0.58). Rates of very late (1 year) definite/
robable stent thrombosis were also similar between both
roups (DES 1.3% vs. BMS 1.8%, p  0.75). By multivari-
PCI of a CTO
; other abbreviations as in Figure 2.Failedble analysis, DES use was the only significant independent
g
t
w
w
p
o
u
c
P
D
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 9 , 2 0 1 1 Mehran et al.
S E P T E M B E R 2 0 1 1 : 9 5 2 – 6 1 Long-Term Outcome After CTO PCI
957predictor of freedom from TVR up to 5 years (HR: 0.52,
95% CI: 0.39 to 0.70, p  0.01).
PES versus SES. Table 4 shows baseline demographic, an-
iographic, and procedural characteristics for patients
reated with PES (n  206) or SES (n  555). Compared
ith patients treated with SES, patients treated with PES
ere more likely to have hypertension and a history of a
rior MI. Moreover, patients treated with PES had shorter
cclusion lengths and a smaller amount of contrast medium
sage. Kaplan-Meier estimates of the various long-term
linical event rates were similar for patients treated with
ES and SES.
iscussion
The main findings of this analysis in a large prospective
multinational CTO registry are: 1) after multivariate anal-
ysis, successful CTO PCI was associated with reduced
cardiac mortality and a trend toward lower all-cause mor-
tality at long-term follow-up; 2) successful CTO PCI is an
independent predictor of a reduced rate of CABG up to
long-term follow-up; 3) use of DES compared with BMS is
associated with a 48% reduction in the need for TVR at
long-term follow-up; 4) rates of overall and very late
definite/probable stent thrombosis were similar for patients
treated with DES and BMS; and 5) the long-term clinical
outcome was similar for patients treated with PES and SES.
Thus far, no randomized controlled trial has been con-
ducted to investigate the effect of CTO recanalization on
clinical endpoints. Previous cohort studies have reported
Table 2. Independent Predictors of All-Cause Mortality, Cardiac Mortality,
MI, and CABG up to 5-Year Follow-Up in All Patients Who Underwent
Attempted PCI of a CTO
HR 95% CI p Value
Independent predictors of all-cause mortality
CKD 2.72 1.37–5.39 0.01
Diabetes mellitus 2.02 1.25–3.26 0.01
Age (per-yr increment) 1.09 1.06–1.11 0.01
Procedural success of CTO 0.63 0.40–1.00 0.05
Independent predictors of cardiac mortality
CKD 6.34 2.87–14.03 0.01
Age (per-yr increment) 1.07 1.03–1.10 0.01
Baseline LVEF (per-10% increment) 0.93 0.91–0.95 0.01
Procedural success of CTO 0.40 0.21–0.75 0.01
Independent predictors of MI
CKD 2.50 1.08–5.75 0.03
Independent predictors of CABG
CTO located in LAD 1.88 1.16–3.06 0.01
Hypercholesterolemia 0.56 0.35–0.91 0.02
Procedural Success of CTO 0.21 0.13–0.36 0.01
CI  confidence interval; HR  hazard ratio; LVEF  left ventricular ejection fraction; other
abbreviations as in Table 1.inconsistent results with regard to improved survival withsuccessful versus failed CTO PCI (3,9,10,15). A recent
meta-analysis on mortality with successful versus failed
CTO PCI in 13 nonrandomized cohort studies showed a
significant 44% reduction in mortality with successful CTO
PCI (11). However, due to the nature of such an analysis of
nonrandomized cohort studies, this might at least in part be
a result of a less favorable clinical profile of patients with
failed PCI rather than the beneficial effect of recanalizing a
CTO. The results from the present study reinforce this
hypothesis, because unadjusted 5-year Kaplan-Meier esti-
mates of mortality were significantly lower in successful
PCI, whereas only a strong trend toward lower mortality
remained after multivariate adjustment. The large Open
Artery Trial randomized recent rather than “chronic” occlu-
sions and reported no benefit after PCI of occluded infarct-
related arteries (16). By contrast, CTO revascularization has
been shown to improve left ventricular function and reduce
predisposition to ventricular arrhythmias (17–19). More-
Table 3. Baseline Demographic, Angiographic, and Procedural
Characteristics of Patients With Successful PCI of a CTO Treated
With BMS and DES
BMS
(n  396)
DES
(n  764) p Value
Baseline characteristics
Age (yrs) 61.8 11.1 61.0 10.7 0.38
Male 87.6% 83.8% 0.08
Hypertension 52.3% 64.9% 0.01
Smoking 11.9% 37.9% 0.01
Diabetes mellitus 15.9% 27.7% 0.01
Hypercholesterolemia 53.8% 76.2% 0.01
Prior MI 64.4% 36.0% 0.01
Prior CABG 14.4% 12.8% 0.46
Ejection fraction 53.8 10.5 53.9 9.7 0.86
CKD 1.3% 4.2% 0.01
Angiographic and procedural
characteristics
Number of revascularized CTOs 1.02 0.15 1.03 0.16 0.48
CTO located in 0.33
LAD 34.8% 38.2%
Circumﬂex 27.0% 21.7%
RCA 39.6% 42.1%
Left main 0.5% 0.4%
Multivessel disease 73.2% 59.4% 0.01
CTO length (mm) 17.1 10.4 23.5 16.4 0.01
Number of stents 1.3 0.9 1.8 0.9 0.01
Stent length (mm) 27.4 19.7 48.4 24.4 0.01
Double coronary injection 17.0% 34.8% 0.01
Residual dissection 4.0% 4.1% 0.97
Coronary perforation during
procedure
0.5% 2.4% 0.02
Total amount of contrast used 383 113 480 220 0.12
Values are mean SD or %.Abbreviations as in Table 1.
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958over, this is consistent with our finding of reduced cardiac
mortality after successful CTO procedures.
It is possible that a survival benefit after successful
recanalization of a CTO might be limited to certain
subgroups. Safley et al. (20) reported a significant benefit in
Figure 4. Clinical Event Rates in Patients Who Underwent Successful PCI
Unadjusted Kaplan-Meier rates plotted. BMS  bare-metal stent(s); DES  dru
adverse cardiac events; TVR  target vessel revascularization; ST  stent thromsurvival after successful PCI of a CTO located in the LADbut not after successful PCI of a CTO located in the
circumflex or right coronary arteries. Moreover, the pres-
ence of a CTO in a noninfarct-related artery was recently
identified as an independent predictor of mortality after
ST-segment elevation MI, and a multicenter randomized
ere Treated With BMS and DES
ng stent(s); PCI  percutaneous coronary intervention; MACE  major
.and W
g-elutitrial is currently ongoing to investigate a clinical benefit of
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959opening a CTO within 1 week after an acute ST-segment
elevation MI (21,22).
Successful CTO PCI in the current study was associated
with a reduced need for subsequent CABG (11), consistent
with previous publications. This reduction in subsequent
CABG can, for the greatest part, be explained by the fact
that patients with failed percutaneous revascularization are
more likely to be referred for surgical revascularization than
to be treated medically. This validates the clinical need for
having appropriately attempted the CTO PCI procedure.
Clinical outcome with BMS versus DES for CTOs. The current
rticle is the first to report on long-term 5-year safety and
fficacy outcomes of DES for the treatment of CTOs. At
ong-term follow-up, the use of DES compared with BMS
Table 4. Baseline Demographic, Angiographic, and P
of a CTO Treated With PES or SES
Baseline characteristics
Age (yrs)
Male
Hypertension
Smoking
Diabetes mellitus
Hypercholesterolemia
Prior MI
Prior CABG
Ejection fraction (%)
CKD
Angiographic and procedural characteristics
Number of revascularized CTOs
CTO located in
LAD
Circumﬂex
RCA
Left main
Multivessel disease
CTO length (mm)
Number of stents
Stent length (mm)
Double coronary injection
Residual dissection
Coronary perforation during procedure
Total amount of contrast used (ml)
Kaplan-Meier estimates of 5-yr clinical outcomes
Major adverse cardiovascular events
Death
MI
Target vessel revascularization
Deﬁnite/probable stent thrombosis
Values are mean SD or %.
Abbreviations as in Table 1.as associated with significantly reduced rates of MACE, Bntirely due to lower rates of TVR. A meta-analysis of 14
onrandomized studies comparing BMS and DES in
TOs reported a significant 60% reduction in TVR, in
ccordance with this study, but there was a strong trend
oward higher rates of stent thrombosis up to 3-year
ollow-up after DES, not observed in this study (13). A
ecent study by Han et al. (23) reported a comparable 5-year
VR rate of 18.4% with DES (SES and PES) for the
reatment of CTOs. However, these investigators did not
eport stent thrombosis rates. The 5-year incidence of
efinite/probable stent thrombosis in the present study was
omparable between DES and BMS. A differential use of
ual antiplatelet therapy (longer after DES) as well as a
ifferent sensitivity to detect late stent thrombosis (lower in
ural Characteristics of Patients With Successful PCI
PES
 206)
SES
(n  555) p Value
.3 10.6 60.9 10.7 0.98
80.6% 84.9% 0.16
71.4% 62.4% 0.03
35.0% 39.0% 0.32
31.0% 26.4% 0.21
74.5% 76.4% 0.59
43.6% 33.1% 0.01
14.1% 12.4% 0.53
.2 9.1 54.1 10.0 0.47
4.5% 4.2% 0.85
2 0.15 1.03 0.16 0.67
0.21
33.0% 40.2%
21.4% 21.8%
48.1% 40.0%
0% 0.5%
62.8% 57.8% 0.25
.4 13.3 24.4 17.0 0.01
.8 1.0 1.9 0.9 0.79
.6 23.6 49.6 24.6 0.31
32.4% 35.8% 0.38
5.9% 3.4% 0.13
3.4% 2.0% 0.25
5 197 486 227 0.03
22.5% 24.4% 0.73
2.1% 6.9% 0.21
6.5% 3.9% 0.49
16.2% 17.2% 0.77
1.2% 2.1% 0.19roced
(n
61
53
1.0
20
1
45
45MS era) might have affected our results in both directions.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 9 , 2 0 1 1
S E P T E M B E R 2 0 1 1 : 9 5 2 – 6 1
Mehran et al.
Long-Term Outcome After CTO PCI
960Clinical outcome with SES versus PES in CTOs. Only 2
previous small-sized cohort studies compared the use of
SES versus PES for the treatment of CTO (24). At a mean
follow-up of 2 years, Lee et al. (24) reported significantly
reduced rates of TVR (SES 9.7% vs. PES 23.9%, p  0.01)
and MI (SES 3.1% vs. PES 7.6%, p  0.04) with SES in a
cohort of 200 patients. The other study, which compared 76
patients treated with SES and 57 patients with PES,
showed no differences in TVR at 400-day follow-up be-
tween SES and PES (2.6% and 3.6%, respectively) (25).
Likewise, in the present report, we observed no significant
differences in clinical TVR and MI with PES or SES in a
significantly larger cohort (n 761). Our result might differ
from those by Lee et al. (24) at least in part, due to the lack
of routine angiographic follow-up in the current study
compared with a 58% routine angiographic follow-up in
the study by Lee et al. (24). The PES are known to cause
higher late loss in a more diffuse pattern and therefore
might be more susceptible to the “oculostenotic reflex”
than SES. At the same time, the PES group in our study
had shorter lesions at baseline, which should have theo-
retically predisposed to a lower restenosis risk.
Data on the use of PES versus BMS in CTO are scarce
but consistent; Werner et al. (26) reported significantly
reduced 1-year MACE rates in a cohort of 48 PES-treated
CTO patients and 48 matched BMS-treated CTO patients
(PES 12.5% vs. BMS 47.9%). More data are available on
the use of SES in CTOs; 2 randomized trials showed
reduced rates of TVR with SES compared with BMS up to
2-year and 3-year follow-up, respectively (27,28). Stent
thrombosis rates with SES in these studies were 1.4% and
5%, respectively. In light of the wide range of stent
thrombosis rates reported in randomized clinical trials and
the scarcity of long-term data on the use of PES and SES
in CTOs, our data show that the use of PES and SES result
in similar clinical outcome and have similar, acceptable rates
of stent thrombosis at long-term follow-up.
Study limitations. This study was not a randomized study
but a registry with prospectively collected data from 3
tertiary referral centers around the world. We had no
information on earlier CTO attempts in other hospitals.
Moreover, no information on fluoroscopy time was available
in our database. Detailed information on peri- and post-
procedural medical therapy was not available; therefore we
were not able to assess adherence to guideline-based post-
PCI therapies. Although we used multivariate Cox regres-
sion analysis including a large number of covariates to adjust
for differences in baseline characteristics, it is still possible
that we did not include potentially unknown confounding
variables in the multivariate model. This is a particularly
important limitation for the DES versus BMS analysis,
because the choice to implant a BMS in the DES era is
often because of a contra-indication to prolonged dual
antiplatelet therapy or significant comorbidity. Nonetheless,the acceptable stent thrombosis rates in both DES and
BMS in this very large cohort of patients with CTO PCI
indicate the long-term safety of DES in these complex
lesions, often requiring multiple long stents. Finally, the
safety and efficacy of next-generation DES might differ
from that of the first-generation SES and PES, which were
predominantly used in this multinational registry.
Conclusions
Successful CTO PCI is associated with reduced long-term
cardiac mortality and reduced need for CABG. Treatment
of CTO with DES rather than BMS is associated with a
significant reduction in TVR with similar rates of stent
thrombosis. The PES and SES had similar long-term safety
and efficacy outcomes.
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